Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784571 | 0.93 | TRPV1 (0.41) | TRPV1PRMT3ROCK2F10 | |
| SCHEMBL785135 | 0.91 | POLB (0.39) | POLBMAPTKDM4EJAK2JAK1 | |
| SCHEMBL784649 | 0.88 | TAS1R3 (0.41) | TRPV1JAK2JAK1PRMT3CTSS | |
| SCHEMBL785714 | 0.88 | TRPV1 (0.38) | TRPV1JAK2JAK1PRMT3F10 | |
| SCHEMBL785325 | 0.87 | SMN1; SMN2 (0.41) | TRPV1POLBMAPTKDM4EJAK2 | |
| SCHEMBL784402 | 0.87 | CTSS (0.40) | JAK2JAK1F10CTSS | |
| SCHEMBL785878 | 0.87 | CTSS (0.40) | TRPV1POLBMAPTKDM4EJAK2 | |
| SCHEMBL784714 | 0.86 | TRPV1 (0.42) | TRPV1JAK2JAK1PRMT3 | |
| SCHEMBL785530 | 0.85 | JAK2 (0.37) | JAK2JAK1F10CTSSMRGPRX2 | |
| SCHEMBL785593 | 0.85 | GHSR (0.40) | TRPV1POLBMAPTKDM4EJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TRPV1 21/4885POLB 3355/4885MAPT 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.